Pre-clinical findings support the potential use of RhoVac’s drug candidate, onilcamotide, across several cancers
RhoVac AB (“RHOVAC”) today, 18[th] May 2022, announces preclinical findings from its collaboration with St. John’s Research Institute (SJRI), a unit of CBCI Society for Medical Education, in Bangalore India. These findings support the hypothesised tissue agnostic mode of action of onilcamotide. The findings identify the crucial MHC-II expression in more tumour cells than was previously known, and they also show co-localisation of the MHC-II receptors and onilcamotide’s target protein, RhoC.In order for a T-cell based cancer vaccine to work, it must be able to induce T cell recognition and
The environmental friendliness of a product is not determined only by its contents. Sustainability must be viewed from the perspective of the product’s entire life cycle, so it’s no wonder that laypersons can be confused by the terminology.Environmental impacts are reduced in a number of ways, starting from the raw materials, manufacturing and packaging to logistics, modes of use and, eventually, disposal. Product development professionals are working hard to always find new and advanced ways to make products more environmentally friendly.
What’s the difference between biodegradable and
